Literature DB >> 22586011

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.

Anna S F Lok1, John W Ward, Robert P Perrillo, Brian J McMahon, T Jake Liang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22586011      PMCID： PMC3469313          DOI： 10.7326/0003-4819-156-10-201205150-00013

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  19 in total

1.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

2.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

3.  Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists.

Authors:  Fiona L Day; Emma Link; Karin Thursky; Danny Rischin
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

4.  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.

Authors:  W Yeo; P K Chan; S Zhong; W M Ho; J L Steinberg; J S Tam; P Hui; N W Leung; B Zee; P J Johnson
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

Review 5.  Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.

Authors:  Matthew B Carroll; Michael A Forgione
Journal:  Clin Rheumatol       Date:  2010-06-16       Impact factor: 2.980

6.  Reactivation of hepatitis B.

Authors:  Jay H Hoofnagle
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

Review 7.  Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.

Authors:  Rohit Loomba; Ayana Rowley; Robert Wesley; T Jake Liang; Jay H Hoofnagle; Frank Pucino; Gyorgy Csako
Journal:  Ann Intern Med       Date:  2008-04-01       Impact factor: 25.391

8.  A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.

Authors:  Chiun Hsu; Chao A Hsiung; Ih-Jen Su; Wei-Shou Hwang; Ming-Chung Wang; Sheng-Fung Lin; Tseng-Hsi Lin; Hui-Hua Hsiao; Ji-Hsiung Young; Ming-Chih Chang; Yu-Min Liao; Chi-Cheng Li; Hung-Bo Wu; Hwei-Fang Tien; Tsu-Yi Chao; Tsang-Wu Liu; Ann-Lii Cheng; Pei-Jer Chen
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

9.  Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.

Authors:  Tak Mao Chan; Guo Xiang Fang; Colin S o Tang; Ignatius K p Cheng; Kar Neng Lai; Stephen K n Ho
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

10.  American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.

Authors:  Andrew S Artz; Mark R Somerfield; Jordan J Feld; Andrew F Giusti; Barnett S Kramer; Anita L Sabichi; Robin T Zon; Sandra L Wong
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544
View more
  27 in total

1.  Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.

Authors:  Arpan Patel; Suna Yapali; Anna S F Lok
Journal:  Hepatol Int       Date:  2015-08-14       Impact factor: 6.047

Review 2.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

Authors:  Rohit Loomba; T Jake Liang
Journal:  Gastroenterology       Date:  2017-02-20       Impact factor: 22.682

3.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

4.  Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis.

Authors:  Tzu-Chieh Lin; Kazuki Yoshida; Sara K Tedeschi; Mirhelen Mendes de Abreu; Nikroo Hashemi; Daniel H Solomon
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-04-12       Impact factor: 4.794

5.  Screening for hepatitis B in patients with lymphoma.

Authors:  Jonathan Ramirez; Anupama Thadareddy Duddempudi; Moazzam M Sana; Syed S Hasan; Mario de Los Santos; Juhee Song; Ying Fang-Hollingsworth; Sandeep S Gupta; Dawn M Sears
Journal:  Proc (Bayl Univ Med Cent)       Date:  2015-10

6.  Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care.

Authors:  Brian McMahon; Joan Block; Timothy Block; Chari Cohen; Alison A Evans; Anu Hosangadi; W Thomas London; Morris Sherman
Journal:  J Natl Cancer Inst       Date:  2015-11-30       Impact factor: 13.506

7.  Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Authors:  Michael R Grever; Omar Abdel-Wahab; Leslie A Andritsos; Versha Banerji; Jacqueline Barrientos; James S Blachly; Timothy G Call; Daniel Catovsky; Claire Dearden; Judit Demeter; Monica Else; Francesco Forconi; Alessandro Gozzetti; Anthony D Ho; James B Johnston; Jeffrey Jones; Gunnar Juliusson; Eric Kraut; Robert J Kreitman; Loree Larratt; Francesco Lauria; Gerard Lozanski; Emili Montserrat; Sameer A Parikh; Jae H Park; Aaron Polliack; Graeme R Quest; Kanti R Rai; Farhad Ravandi; Tadeusz Robak; Alan Saven; John F Seymour; Tamar Tadmor; Martin S Tallman; Constantine Tam; Enrico Tiacci; Xavier Troussard; Clive S Zent; Thorsten Zenz; Pier Luigi Zinzani; Brunangelo Falini
Journal:  Blood       Date:  2016-11-30       Impact factor: 22.113

Review 8.  Does antiviral therapy reduce complications of cirrhosis?

Authors:  Goh Eun Chung; Jeong-Hoon Lee; Yoon Jun Kim
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 9.  Prevention and management of hepatitis B virus reactivation in cancer patients.

Authors:  Ka-Shing Cheung; Wai-Kay Seto; Ching-Lung Lai; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2016-01-06       Impact factor: 6.047

Review 10.  Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.

Authors:  Sonali Paul; Akriti Saxena; Norma Terrin; Kathleen Viveiros; Ethan M Balk; John B Wong
Journal:  Ann Intern Med       Date:  2015-11-24       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.